Skin patch could be solution for peanut allergy, study suggests


DBV Technologies recently conducted an exciting clinical trial for families with children who have a peanut allergy. The results were published in the scientific journal New England Journal of Medicine. The phase three clinical trial focused on a new epicutaneous immunotherapy patch specifically designed to reduce peanut allergy in children aged one to three years. This promising approach offers new hope for parents and clinicians in managing this common childhood allergy.

 

 

How was this study carried out?

In the study, a total of 362 participants were recruited and divided into two groups. While one group received daily doses of 250 micrograms of a peanut protein via the patch, the other group received a placebo. Over a period of 12 months, participants were monitored.

The results of the analysis indicated that 67% of the children who used the patch achieved the main objective of the study, which was to desensitize children to peanuts and increase the tolerated dose of the substance that triggered allergic symptoms.

In contrast, only 33.5% of the placebo group achieved this goal. In addition, the group that received the patch had less severe reactions compared to the placebo group. These results are encouraging and suggest that the epicutaneous immunotherapy patch may be effective in treating peanut allergy in children.